Skip to main content

Table 2 Efficacy of methylphenidate on the simplified Conners’ rating scale and other secondary endpoints

From: The effect of methylphenidate on neurofibromatosis type 1: a randomised, double-blind, placebo-controlled, crossover trial

  Within-patient difference MPD effect
  MPD Placebo  
Parent’s version (Main endpoint) -5.7 (-7.3, -4.1) -1.8 (-3.4, -0.1) -3.9 (-6.1, -1.7)
Teacher’s version -3.5 (-5.8, -1.2) -1.6 (-3.8, 0.6) -1.9 (-5.0, 1.1)*
CDRs -2.9 (-5.0, -0.9) -1.9 (-4.0, 0.2) -1.1 (-4.0, 1,8)
CDI -2.1 (-3.9, -0.4) -1.9 (-3.7, -0.1) -0.2 (-2.7, 2.3)
STAIc-state -3.2 (-5.1, -1.2) -1.9 (-3.8, 0.1) -1.3 (-4.0, 1.4)
STAIc-trait -3.1 (-5.2, -1.0) -2.7 (-4.8, -0.6) -0.3 (-3.3, 2.6)
  1. *NS, 50% of data were missing.
  2. Mean variation (95% confidence limits).